Camptothecine (CPT) is an important anti-cancer compound obtained from several plant species belonging to the Asterid clade 1. It is a potent inhibitor of the intra-nuclear enzyme topoisomerase-I, which is required in DNA replication and transcription 2.Several semi-synthetic drugs, such as, Hycamtin (topotecan) and Camptostar (irinotecan or CPT 11) are derived from CPT and are currently in clinical use against ovarian, small lung and refractory ovarian cancer1,3-5. Recently, CPT has also been reported from yet another plant, Miquelia dentata Bedd., belonging to the family Icacinaceae, sub-order,Asterid6, 7.The fruits of the plant produce the highest ever reported content of CPT, ranging from 0.8 to 1.2 per cent by dry wt.This species is a slow growing climber and is sparsely distributed in the Western Ghats, India 8.Despite the discovery of several species producing CPT, an inherent constraint is the sustainable extraction of CPT; most of the extraction is done by destructive felling of the woody trees and plants. The heavy demand for CPT has resulted in extensive harvesting of two of the most important plant species producing CPT, namely, Campotheca acuminata (in China) and Nothapodytes nimmoniana (in India). In fact, consequent to the indiscriminate harvesting, both the species are threatened; N. nimmoniana has been declared as vulnerable in India 9 .Against this background, several attempts have made to explore plant cell culture approaches for a more stable production of CPT from C. accuminata10,11 N. nimmoniana12 and O. pumila13. In the present study, we report the development of callus cultures from leaf explants of M. dentata, which are able to produce CPT and its analog, MCPT (methoxy campothecine). These findings are also discussed in context to the development of stable in vitro production system for CPT.